Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Xia, Ming Feng ^a   Yki Järvinen, Hannele ^b,c   Bian, Hua ^a   Lin, Huan Dong ^a   Yan, Hong Mei ^a   Chang, Xin Xia ^a   Zhou, You ^b,c   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF HELSINKI   (Finland)

^c MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN;

ADULT; ARTICLE; AST ALT RATIO; BODY MASS; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; ETHNIC DIFFERENCE; FATTY LIVER INDEX; FEMALE; FINN (PEOPLE); HAN CHINESE; HEPATIC STEATOSIS INDEX; HEPATOBILIARY PARAMETERS; HUMAN; INSULIN BLOOD LEVEL; LIVER FAT CONTENT; LIVER FAT SCORE; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER FAT SCORE; NUCLEAR MAGNETIC RESONANCE SCANNER; OBESITY; PROTON NUCLEAR MAGNETIC RESONANCE; REAL TIME ULTRASOUND SCANNER; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; WAIST CIRCUMFERENCE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CAUCASIAN; CHINA; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; ETHNOLOGY; FINLAND; MIDDLE AGED; MULTICENTER STUDY; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHINA; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FINLAND; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84990251388     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0160526     Document Type: Article

References (36)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142:1592-1609. doi: 10.1053/j.gastro.2012.04.001 PMID: 22656328
2. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol. 2008; 48 (Suppl 1): S104-112. doi: 10.1016/j.jhep.2008.01.009 PMID: 18304679
3. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9(6):524-530. doi: 10.1016/j.cgh.2011.03.020 PMID: 21440669
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10(6):330-344. doi: 10.1038/nrgastro.2013.41 PMID: 23507799
5. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F.Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance.J Hepatol. 2009; 51(3):433-445. doi: 10.1016/j.jhep.2009.05.023 PMID: 19604596
6. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51:1061-1067. doi: 10.1016/j.jhep.2009.09.001 PMID: 19846234
7. Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity (Silver Spring). 2012; 20:444-452.
8. Gao X, Fan J. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: Consensusstatement from the Study Group of Liver and Metabolism,Chinese Society of Endocrinology. J Diabetes. 2013; 5:406-415. doi: 10.1111/1753-0407.12056 PMID: 23560695
9. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137:865-872. doi: 10.1053/j.gastro.2009.06.005 PMID: 19524579
10. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6:33. PMID: 17081293
11. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4:10. PMID: 16375767
12. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42:503-508. doi: 10.1016/j.dld.2009.08.002 PMID: 19766548
13. Etler DA. Recent developments in the study of human biology in China: a review.Hum Biol. 1992; 64 (4):567-585. PMID: 1644424
14. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2:901-910. doi: 10.1016/S2213-8587(14)70032-4 PMID: 24731669
15. Gao X, Hofman A, Hu Y, Lin H, Zhu C, Jeekel J, et al. The Shanghai Changfeng Study: A community-based prospective cohort study of chronic diseases among middle-aged and elderly: Objectives and design. Eur. J. Epidemiol.2010; 25: 885-893. doi: 10.1007/s10654-010-9525-6 PMID: 21120588
16. Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22:775-777. PMID: 17565629
17. Bian H, Yan H, Zeng M, Rao S, Yao X, Zhou J, et al. Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol Ther. 2011; 13:149-155. doi: 10.1089/dia.2010.0101 PMID: 21284482
18. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288:E462-468. PMID: 15339742
19. Li X, Xia M, Ma H, Hofman A, Hu Y, Yan H, et al. Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study. Atherosclerosis. 2012; 224:480-485. doi: 10.1016/j.atherosclerosis.2012.07.002 PMID: 22884916
20. Perkins NJ, Schisterman EF. The inconsistency of 'optimal' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am. J. Epidemiol. 2006; 163: 670-675. PMID: 16410346
21. Akobeng AK.Understanding diagnostic tests 3: Receiver operating characteristic curves.Acta Paediatr. 2007; 96(5):644-647. PMID: 17376185
22. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009; 50 (1):204-210. doi: 10.1016/j.jhep.2008.10.010 PMID: 19014878
23. Xia MF, Yan HM, Lin HD, Bian H, Pan BS, Yao XZ, et al. Elevation of liver enzymes within the normal limits and metabolic syndrome. Clin Exp Pharmacol Physiol. 2011; 38(6):373-379. doi: 10.1111/j.1440-1681.2011.05519.x PMID: 21418268
24. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease.Proc Natl Acad Sci U SA. 2011; 108(39):16381-16385.
25. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 2002; 3:141-146. PMID: 12164465
26. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.Circulation. 2009; 120(16):1640-1645. doi: 10.1161/CIRCULATIONAHA.109.192644 PMID: 19805654
27. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.NatGenet. 2008; 40(12):1461-1465.
28. Zhou Y, Llauradó G, Orešič M, Hyötyläinen T, Orho-Melander M, Yki-Järvinen H.Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant inTM6SF2.J Hepatol. 2015; 62(3):657-663. doi: 10.1016/j.jhep.2014.10.010 PMID: 25457209
29. Xia MF, Ling Y, Bian H, Lin HD, Yan HM, Chang XX, et al. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.Aliment Pharmacol Ther. 2016; 43(5):631-642. doi: 10.1111/apt.13521 PMID: 26765961
30. Peng XE, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X. Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One. 2012; 7(11):e50256. doi: 10.1371/journal.pone.0050256 PMID: 23226254
31. Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology. 2014; 59(6):2170-2177. doi: 10.1002/hep.26767 PMID: 24114809
32. Hyysalo J, Gopalacharyulu P, Bian H, Hyötyläinen T, Leivonen M, Jaser N, et al. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant inPNPLA3 and with obesity. Diabetes. 2014; 63(1):312-322. doi: 10.2337/db13-0774 PMID: 24009255
33. Wang X, Liu Z, Peng Z, Liu W. The TM6SF2 rs58542926 T allele is significantly associated with non-alcoholic fatty liver disease in Chinese. J Hepatol. 2015; 62(6):1438-1439. doi: 10.1016/j.jhep.2015.01.040 PMID: 25687425
34. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, ZhouHH, Tybjærg-Hansen A. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014; 46(4):352-356. doi: 10.1038/ng.2901 PMID: 24531328
35. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015; 61(2):506-514. doi: 10.1002/hep.27490 PMID: 25251399
36. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications forprognosis and clinical management.J Hepatol. 2015; 62(5):1148-1155. doi: 10.1016/j.jhep.2014.11.034 PMID: 25477264